Mark S. Blumenkranz
Dr. Blumenkranz has served as a member of our board of directors since November 2021. He is an ophthalmologist and vitreoretinal surgeon who is Chairman and CEO of Kedalion Therapeutics. He is also H.J. Smead Professor Emeritus in the Department of Ophthalmology at Stanford University where he served as Chairman from 1997 to 2015. Dr. Blumenkranz is an internationally known vitreo-retinal specialist, with notable contributions in the area of new laser systems, novel pharmaceuticals for macular diseases, ocular gene therapy and ophthalmic tele-health and technology development. Over the course of his career, Dr. Blumenkranz held leadership roles at Oculex Pharmaceuticals (acquired by Allergan), Macusight (acquired by Santen), Peak Surgical (acquired by Medtronics), Optimedica (acquired by AMO), and Oculeve (acquired by Allergan), as well as Adverum, where he served as both co-founder and Chairman of the Board. He is also co-founder and served as a director of Verana Health for ten years, and currently serves as Managing Director of Lagunita Biosciences, a biotechnology and medical investment company and incubator in Menlo Park California. Dr. Blumenkranz received his Undergraduate, Master’s in Biochemical Pharmacology, and M.D. at Brown University, completed his Ophthalmic residency training at Stanford University, and his Fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute.